ARST1431: A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI Torisel NSC# 683864 IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma
Brief description of study
If you or your child have been diagnosed with rhabdomyosarcoma (RMS) a type of cancer that occurs in the soft tissues of the body like the muscles, you or your child may qualify to participate in a study evaluating an experimental drug called temsirolimus when added to VAC/VI therapy. The goal of this phase 3 study is to compare the effects, good and/or bad, of a new combination of chemotherapy using VAC/VI plus temsirolimus. In addition, this study aims find if adding the drug temsirolimus to VAC/VI therapy will get rid of the cancer better than VAC/VI by itself.
Clinical Study Identifier: s16-01680
ClinicalTrials.gov Identifier: NCT02567435
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
